The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death

Toxicology in Vitro

Volumn 29, Issue 4, 2015, Pages 732-740

  Kamalian, Laleh ^a   Chadwick, Amy E ^a   Bayliss, Mark ^a   French, Neil S ^a   Monshouwer, Mario ^b   Snoeys, Jan ^b   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Drug induced liver injury; Dysfunction; HepG2; Mitochondria; Toxicity

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMIODARONE; BOSENTAN; BUSPIRONE; DICLOFENAC; ENTACAPONE; MELAGATRAN; METFORMIN; NEFAZODONE; PARACETAMOL; PERHEXILINE; PIOGLITAZONE; TOLCAPONE; TROGLITAZONE; LACTATE DEHYDROGENASE;

ACIDIFICATION; ARTICLE; CELL DEATH; CELL LEVEL; CELL RESPIRATION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CYTOTOXICITY; ELECTRON TRANSPORT; HEPG2 CELL LINE; OXYGEN CONSUMPTION; TOXIC HEPATITIS; CELL SURVIVAL; CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; LIVER MITOCHONDRION; METABOLISM; PATHOLOGY;

ADENOSINE TRIPHOSPHATE; CELL DEATH; CELL SURVIVAL; DRUG-INDUCED LIVER INJURY; HEP G2 CELLS; HUMANS; L-LACTATE DEHYDROGENASE; MITOCHONDRIA, LIVER; MITOCHONDRIAL DISEASES; OXYGEN CONSUMPTION;

EID: 84924984759     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2015.02.011     Document Type: Article

References (28)

1. Boelsterli U.A., Lim P.L.K. Mitochondrial abnormalities - a link to idiosyncratic drug hepatotoxicity?. Toxicol. Appl. Pharmacol. 2007, 220:92-107.
2. Clement B., Lopian K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab. Dispos. 2003, 31:645-651.
3. Dykens J.A., Jamieson J.D., Marroquin L.D., Nadanaciva S., Xu J.J., Dunn M.C., Smith A.R., Will Y. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol. Sci. 2008, 103:335-345.
4. Eriksson U.G., Bredberg U., Hoffmann K.J., Thuresson A., Gabrielsson M., Ericsson H., Ahnoff M., Gislen K., Fager G., Gustafsson D. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab. Dispos. 2003, 31:294-305.
5. Fattinger K., Funk C., Pantze M., Weber C., Reichen J., Stieger B., Meier P.J. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 2001, 69:223-231.
6. Fischer J.J., Michaelis S., Schrey A.K., Baessler O.G.N., Glinski M., Dreger M., Kroll F., Koester H. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two parkinson drugs. Toxicol. Sci. 2010, 113:243-253.
7. Fromenty B., Fisch C., Berson A., Letteron P., Larrey D., Pessayre D. Dual effect of amiodarone on mitochondrial respiration - initial protonophoric uncoupling effect followed by inhibition of the respiratory-chain at the levels of Complex-I and Complex-Ii. J. Pharmacol. Exp. Ther. 1990, 255:1377-1384.
8. Gerets H.H.J., Tilmant K., Gerin B., Chanteux H., Depelchin B.O., Dhalluin S., Atienzar F.A. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol. Toxicol. 2012, 28:69-87.
9. Hussaini S.H., Farrington E.A. Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Expert Opin. Drug Safety 2014, 13:67-81.
10. Kenne K., Skanberg I., Glinghammar B., Berson A., Pessayre D., Flinois J.P., Beaune P., Edebert I., Pohl C.D., Carlsson S., Andersson T.B. Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol. In Vitro 2008, 22:730-746.
11. Kennedy J.A., Unger S.A., Horowitz J.D. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem. Pharmacol. 1996, 52:273-280.
12. Korlipara L.V., Cooper J.M., Schapira A.H. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. Neuropharmacol. 2004, 46:562-569.
13. Kon K., Kim J.S., Jaeschke H., Lemasters J.J. Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. Hepatology 2004, 40:1170-1179.
14. Labbe G., Pessayre D., Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol. 2008, 22:335-353.
15. Lofrumento D.D., La Piana G., Abbrescia D.I., Palmitessa V., La Pesa V., Marzulli D., Lofrumento N.E. Valinomycin induced energy-dependent mitochondrial swelling, cytochrome c release, cytosolic NADH/cytochrome c oxidation and apoptosis. Apoptosis 2011, 16:1004-1013.
16. Marroquin L.D., Hynes J., Dykens J.A., Jamieson J.D., Will Y. Circumventing the crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 2007, 97:539-547.
17. Moreno-Sanchez R., Bravo C., Vasquez C., Ayala G., Silveira L.H., Martinez-Lavin M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs - Study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem. Pharmacol. 1999, 57:743-752.
18. Nadanaciva S., Bernal A., Aggeler R., Capaldi R., Will Y. Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol. In Vitro 2007, 21:902-911.
19. Nelson S.D. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin. Liver Dis. 1990, 10:267-278.
20. Ong M.M.K., Latchoumycandane C., Boelsterli U.A. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol. Sci. 2007, 97:205-213.
21. Parmar D.V., Ahmed G., Khandkar M.A., Katyare S.S. Mitochondrial ATPase: a target for paracetamol-induced hepatotoxicity. Eur. J. Pharmacol. 1995, 293:225-229.
22. Pereira C.V., Oliveira P.J., Will Y., Nadanaciva S. Mitochondrial bioenergetics and drug-induced toxicity in a panel of mouse embryonic fibroblasts with mitochondrial DNA single nucleotide polymorphisms. Toxicol. Appl. Pharmacol. 2012, 264:167-181.
23. Pike L.S., Smift A.L., Croteau N.J., Ferrick D.A., Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta - Bioenergetics 2011, 1807:726-734.
24. Ramachandran A., Lebofsky M., Weinman S.A., Jaeschke H. The impact of partial manganese superoxide dismutase (SOD2)-deficiency on mitochondrial oxidant stress, DNA fragmentation and liver injury during acetaminophen hepatotoxicity. Toxicol. Appl. Pharmacol. 2011, 251:226-233.
25. Scatena R., Martorana G.E., Bottoni P., Giardina B. Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs). IUBMB Life 2004, 56:477-482.
26. Swiss R., Niles A., Cali J.J., Nadanaciva S., Will Y. Validation of a HTS-amenable assay to detect drug-induced mitochondrial toxicity in the absence and presence of cell death. Toxicol. In Vitro 2013, 27:1789-1797.
27. Warburg O. Origin of cancer cells. Science 1956, 123:309-314.
28. Will Y., Dykens J. Mitochondrial toxicity assessment in industry - a decade of technology development and insight. Expert Opin. Drug Metabolism Toxicol. 2014, 10:1061-1067.